Ticketplus Ltd.: Target Price Consensus and Analysts Recommendations | TP | KYG886131070 | MarketScreener

Ticketplus Ltd. (TP) priced its Nasdaq IPO at $8 per share, raising about $15 million by selling 1.875 million shares, according to the IPO pricing details. The offering is led by Roth Capital Partners with Bancroft Capital and MDB Capital, marking the company’s Nasdaq debut.

Ticketplus Ltd. priced its IPO of 1,875,000 ordinary shares at $8.00 each on NYSE American, according to the company. The deal is expected to raise about $15 million in gross proceeds, with a 45-day option for up to 281,250 additional shares. Shares are set to trade under ticker TP on Aug. 7, 2026.

Air France-KLM and Lufthansa Group submitted binding bids to buy 44.9% to 49.9% of TAP Air Portugal from Portugal’s state holding Parpública, without disclosing bid values. Both said they would preserve Lisbon as a hub and expand connectivity, including transatlantic routes. Air France-KLM cited MRO investment plans supported by Delta Air Lines; Lufthansa said TAP is already in Star Alliance and Lisbon would focus on South America.

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.